Inhibition of NLRP3 inflammasome activation could attenuate podocyte injury and improve renal function in kidney diseases caused by various factors (Wu et al., 2018), such as inflammation and lipid metabolism in DN (Wu et al., 2021). Here, NLRP3 is linked to liver dysplastic nodule.